Every 10-Q that Emergent Biosolutions, Inc. (EBS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EBS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EBS filings page.
Emergent BioSolutions Inc. reported Q2 2026 total revenues of $234.3 million, up from $140.9 million a year earlier, driven mainly by MCM Products revenue of $168.0 million versus $58.4 million, while Commercial Products revenue declined to $52.4 million from $67.5 million. First‑half 2026 revenues were $390.4 million versus $363.1 million in 2025.
The company recorded a non‑cash $191.3 million impairment of the NARCAN intangible asset, a $10.7 million loss on Gaithersburg assets held‑for‑sale and a $20.5 million loss on debt extinguishment, leading to a Q2 net loss of $180.2 million and basic/diluted EPS of $(3.49), compared with a $12.0 million loss in Q2 2025. For the first half, net loss was $173.4 million versus $56.0 million of income in 2025.
As of June 30 2026, total assets were $1.12 billion and stockholders’ equity had declined to $341.4 million from $522.6 million at year‑end 2025, reflecting the impairment and losses. Cash, cash equivalents and restricted cash were $140.9 million, operating cash flow was $22.3 million, and total debt remained $589.7 million, including $439.7 million of 3.875% Senior Unsecured Notes and a new $150.0 million term loan maturing in 2031.
During the half, Emergent paid a $50.4 million Ebanga‑related milestone, repurchased 1.9 million shares for $18.2 million under its reauthorized buyback program and reduced its warrant liability to $12.8 million from $21.7 million. Subsequent to quarter‑end, it approved an August 2026 restructuring plan eliminating about 114 positions and closing Gaithersburg wet labs, with expected charges of $10.0–$11.5 million and anticipated annualized savings of over $40.0 million.
Emergent BioSolutions Inc. reported weaker results for the quarter ended March 31, 2026. Total revenues were $156.1 million, down from $222.2 million, mainly from lower medical countermeasure product sales and reduced contracts and grants revenue. Gross margin fell to $61.2 million, or 41% of product and services sales.
Net income dropped to $6.8 million from $68.0 million, with diluted EPS declining to $0.07 from $1.19. Operating cash flow was a net use of $33.8 million. The company ended the quarter with $161.5 million in cash, cash equivalents and restricted cash and total debt of $589.7 million. Subsequent to quarter-end, Emergent entered a new $150 million term loan and amended its revolving credit facility, both maturing in 2031.
Emergent BioSolutions (EBS) reported third‑quarter 2025 results. Total revenue was $231.1 million versus $293.8 million a year ago, while net income was $51.2 million versus $114.8 million. Year‑to‑date, revenue totaled $594.2 million versus $848.9 million, and net income reached $107.2 million compared to a loss of $(159.3) million in 2024, reflecting lower operating expenses and non‑operating gains.
Cash and cash equivalents rose to $245.5 million from $99.5 million at year‑end, supported by $92.9 million in operating cash flow. Inventories were $356.3 million. Gross debt stood at $693.1 million (including $443.1 million of 3.875% Senior Notes due 2028 and a $250.0 million term loan due 2029); net carrying value after issuance costs was $663.1 million. The company repurchased $15.8 million of common stock year‑to‑date.
Strategic actions continued: Emergent recognized $50.0 million in 2025 milestone receipts from the prior Travel Health sale and recorded a $12.2 million loss on assets held for sale related to Maryland warehouse space. As of October 22, 2025, there were 52,519,964 common shares outstanding.